On October 24, 2025, Italfarmaco issued a statement addressing recent online discussions about patient deaths among individuals with Duchenne muscular dystrophy treated with DUVYZAT® (givinostat). The company stated that, based on current data and international standards, these deaths are not linked to the treatment and the medication’s benefit-risk profile remains unchanged. Italfarmaco emphasized its ongoing commitment to patient safety, noting that nearly 2,000 patients have been treated with givinostat, some for over a decade, and that all serious events are reported and reviewed with regulatory authorities.
Read Italfarmaco’s community letter by clicking here.
